Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel biochemical analysis for ApoE4 quantification in plasma and discrimination of homozygous and heterozygous APOE ε4 carriers.

Alzheimer's research & therapy - 15 Jul 2025

Rodríguez Andrés, Calero Olga, Veiga Sergio, Menacho-Román Miriam, Arribas Ignacio, Cano Lluís, García-Ribas Guillermo, Calero Miguel

Abstract excerpt

BACKGROUND: The APOE ε4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) and is associated with increased risk of amyloid-related imaging abnormalities (ARIA) during anti-amyloid therapy. Accurate identification of ε4 carriers, particularly APOE ε4/ε4 individuals, is clinically relevant. This study outlines the development and validation of e4Quant, a novel turbidimetric assay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Apolipoprotein E4

Share to Genotype

Share to Heterozygote

Share to Homozygote

Share to ROC Curve

Source

Open in PubMed Open full text

Identifiers

PMID: 40671162
DOI: 10.1186/s13195-025-01811-w
PMCID: PMC12265242

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel biochemical analysis for ApoE4 quantification in plasma and discrimination of homozygous and heterozygous APOE ε4 carriers.PMID 40671162Read ↗

Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era.Semantic proximity Read ↗

An automated plasma-based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease.Semantic proximity Read ↗

Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods.Semantic proximity Read ↗

Serum as an alternative to plasma for determining the ApoE4 phenotype using Pan-ApoE and ApoE4 chemiluminescent enzyme immunoassays.Semantic proximity Read ↗

Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers.Semantic proximity Read ↗

Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele.Semantic proximity Read ↗

Serum proteomics reveals early biomarkers of Alzheimer's disease: The dual role of APOE-ε4Semantic proximity Read ↗

Apolipoprotein E proteotyping as a valid alternative to genotyping in clinical practice.Semantic proximity Read ↗

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.Semantic proximity Read ↗

Evaluation of two plasma-based proteotyping assays against APOE ε4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies.Semantic proximity Read ↗

A Preliminary Study on Rapid Quantitative and Qualitative Detection Methods for Apolipoprotein E4 in PlasmaSemantic proximity Read ↗

Proteomic Signatures of Protected <i>APOE</i> -ε4 Carriers Reveal Causal Pathways Associated with Delayed Alzheimer’s Disease OnsetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.